News for Benitec Biopharma Inc. (BNTC)

Key Highlights: Benitec Biopharma (BNTC) is executing a $30 million securities offering to strengthen financial resources. Analysts suggest a significant

Benitec Biopharma, denoted by the ticker BNTC, has submitted a filing to initiate the sale of 900,000 common stock shares. This move aims to allow existing shar

Discover key insights on Benitec Biopharma's filing to sell 900K shares. Learn about its impact on stakeholders and market relevance.

On May 15, 2025, Benitec Biopharma (BNTC) received an update from JMP Securities regarding its analyst rating and price target. The stock continues to be rated

Benitec Biopharma (BNTC) has reached a significant milestone in its ongoing efforts to develop BB-301, a gene therapy targeting dysphagia in patients with oculo

HAYWARD, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. ( BNTC) (”œBenitec” or ”œCompany”), a clinical-stage, gene therapy-focused, bio

**media[625376]**

HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. ( BNTC) (”œBenitec” or the ”œCompany”), a clinical-stage, gene therapy-focuse

Benitec Biopharma (BNTC) aims to raise $30M through stock and pre-funded warrant offerings. Proceeds to fund product development and corporate growth.

**media[575919]**

On March 4, 2025, Suvretta Capital Management, LLC executed a strategic acquisition of 4,727,510 shares in Aadi Bioscience Inc, a company specializing in precli

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Friday. Shares of Micron Technology, Inc. MU fell sharply in toda...

Shares of Ouster, Inc. OUST rose sharply in today's pre-market trading after the company reported better-than-expected fourth-quarter financial results. Ouster...

HAYWARD, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. ( BNTC) (”œBenitec” or the ”œCompany”), a clinical-stage, gene therapy-focused

The average of price targets set by Wall Street analysts indicates a potential upside of 127.3% in Benitec Biopharma (BNTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Benitec Biopharma (BNTC) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Transaction Overview On December 31, 2024, Janus Henderson Group PLC executed a strategic transaction involving Benitec Biopharma Inc. The firm reduced its hold

-Fifth Subject in BB-301 Phase 1b/2a Clinical Treatment Study safely treated in February 2025- -Interim clinical study update to be presented in late-breaking

**media[540808]**